Stifel analyst Paul Mattels upgraded Denali Therapeutics Inc. (NASDAQ: DNLI) from Hold to Buy with a price target of $37.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE